Join Growin Stock Community!

Alnylam pharmaceuticals, inc.ALNY.US Overview

US StockHealthcare
(No presentation for ALNY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALNY AI Insights

ALNY Overall Performance

ALNY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALNY Recent Performance

-1.88%

Alnylam pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ALNY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALNY Key Information

ALNY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALNY Profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Price of ALNY

ALNY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALNY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.37
PE Ratio (TTM)
142.88
Forward PE
160.92
PS Ratio (TTM)
11.89
PB Ratio
55.67
Price-to-FCF
93.09
METRIC
VALUE
vs. INDUSTRY
Gross Margin
81.64%
Net Margin
8.45%
Revenue Growth (YoY)
65.19%
Profit Growth (YoY)
57.52%
3-Year Revenue Growth
48.49%
3-Year Profit Growth
42.97%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.37
PE Ratio (TTM)
142.88
Forward PE
160.92
PS Ratio (TTM)
11.89
PB Ratio
55.67
Price-to-FCF
93.09
Gross Margin
81.64%
Net Margin
8.45%
Revenue Growth (YoY)
65.19%
Profit Growth (YoY)
57.52%
3-Year Revenue Growth
48.49%
3-Year Profit Growth
42.97%

  • When is ALNY's latest earnings report released?

    The most recent financial report for Alnylam pharmaceuticals, inc. (ALNY) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALNY's short-term business performance and financial health. For the latest updates on ALNY's earnings releases, visit this page regularly.

  • Where does ALNY fall in the P/E River chart?

    According to historical valuation range analysis, Alnylam pharmaceuticals, inc. (ALNY)'s current price-to-earnings (P/E) ratio is 130.4, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ALNY?

    According to the latest financial report, Alnylam pharmaceuticals, inc. (ALNY) reported an Operating Profit of 131.72M with an Operating Margin of 12.01% this period, representing a growth of 225.26% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ALNY's revenue growth?

    In the latest financial report, Alnylam pharmaceuticals, inc. (ALNY) announced revenue of 1.1B, with a Year-Over-Year growth rate of 84.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ALNY have?

    As of the end of the reporting period, Alnylam pharmaceuticals, inc. (ALNY) had total debt of 2.97B, with a debt ratio of 0.6. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ALNY have?

    At the end of the period, Alnylam pharmaceuticals, inc. (ALNY) held Total Cash and Cash Equivalents of 1.66B, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ALNY go with three margins increasing?

    In the latest report, Alnylam pharmaceuticals, inc. (ALNY) achieved the “three margins increasing” benchmark, with a gross margin of 75.6%%, operating margin of 12.01%%, and net margin of 17%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ALNY's profit trajectory and future growth potential.

  • Is ALNY's EPS continuing to grow?

    According to the past four quarterly reports, Alnylam pharmaceuticals, inc. (ALNY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALNY?

    Alnylam pharmaceuticals, inc. (ALNY)'s Free Cash Flow (FCF) for the period is 140.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 235.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ALNY?

    The latest valuation data shows Alnylam pharmaceuticals, inc. (ALNY) has a Price-To-Earnings (PE) ratio of 130.4 and a Price/Earnings-To-Growth (PEG) ratio of -2.69. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.